This review surveys the developing market for direct-to-consumer (DTC) genetic tests and examines the range of companies and tests available, the regulatory landscape, the concerns raised about DTC testing, and the calls for enhanced oversight. We provide a comparative overview of the situation, particularly in the United States and Europe, by exploring the regulatory frameworks for medical devices and clinical laboratories. We also discuss a variety of other mechanisms such as general controls on advertising and consumer law mechanisms.
No takes yet. Share an insight, caveat, or question.
Hogarth et al. (2008) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: